OBR Daily Commentary

forumImage

Imfinzi Demonstrated Unprecedented Survival In Unresectable, Stage III Non-small Cell Lung Cancer With An Estimated 50% Of Patients Surviving Four Years

(AstraZeneca) Sept 18, 2020 - PACIFIC Phase III trial data at ESMO also showed an estimated 35% of non-small cell lung cancer patients treated with Imfinzi had not progressed after four years. CASPIAN Phase III trial data also at ESMO underscored long-term benefit in a proportion of patients with extensive-stage small cell lung cancer.

H. Jack West, MD (Posted: September 21, 2020)

quotesWe can debate whether we're out far enough to call these patients cured, but seeing a 15% improvement in 4 year OS, now 3 years out or more after having ended durvalumab, represents a remarkable result and huge improvement for patients.quotes

Read Article arrow
Add Comment 2 Comment
forumImage

Imfinzi Demonstrated Unprecedented Survival In Unresectable, Stage III Non-small Cell Lung Cancer With An Estimated 50% Of Patients Surviving Four Years

(AstraZeneca) Sept 18, 2020 - PACIFIC Phase III trial data at ESMO also showed an estimated 35% of non-small cell lung cancer patients treated with Imfinzi had not progressed after four years. CASPIAN Phase III trial data also at ESMO underscored long-term benefit in a proportion of patients with extensive-stage small cell lung cancer.

H. Jack West, MD (Posted: September 18, 2020)

quotesIt's not really fair to compare survival on PACIFIC, which only enrolled patients who had completed chemoradiation without demonstrating progression or a functional decline/significant toxicity, with survival results from trials that start before the chemoradiation, since we know that about a third of patients enrolled on these "all comers" trials progress before getting to the point of consolidation. So PACIFIC is enriched for patients more likely to do well, as evidenced by the fact that the control arm also exceed the oft-cited historical standard of 15-20% long-term survival. But the difference between the two arms on PACIFIC, about 15% is still very important, very impressive, and at 4 years out we're getting to a point where few people should die from recurrent disease if they haven't already. These patients are now 3 or more years out from having completed durvalumab, which should reassure us that the benefit of consolidation durvalumab isn't merely a transient effect while on it. There is a sustained benefit that I think now can be said to be potentially curative effect in this setting.quotes

Read Article arrow
Add Comment 2 Comment
forumImage

With Election Looming, Trump Releases Major, Last-Ditch Drug Pricing Order

(STAT) Sept 13, 2020 - President Trump released an executive order Sunday that would drastically cut how much Medicare pays for virtually all of the drugs seniors take — the boldest move yet he’s taken to lower drug prices since taking office. The policy vastly expands an older, controversial drug pricing policy that Trump has been teasing for months. Effectively, it will force drug makers to offer their medicines to Medicare at the same prices they do in other countries, as a so-called most favored nations policy.

Dean Gesme, MD (Posted: September 14, 2020)

quotesTrump, by Executive Order, invoked his International Pricing Index for BOTH Medicare Part B and Part D as a 5 year demonstration project. It will now require rule-making and legal scrutiny by affected parties but is likely meant primarily as a vote magnet for Seniors.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...